Vol. 6 No. 8 (2026): August
Reimbursement Reviews

Bimekizumab (Bimzelx)

decorative image of the issue cover

Published August 17, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses bimekizumab (Bimzelx), solution for injection (160 mg/1 mL prefilled syringe or autoinjector).
  • Indication: The treatment of adult patients with moderate to severe hidradenitis suppurativa with an inadequate response to conventional systemic therapy.